anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Spontaneous uterine vein rupture in pregnancy is rare. This current case report presents a case of broad ligament vein rupture in spontaneous twin pregnancy that is even rarer. A female in her early 30s at the third trimester of a twin pregnancy presented with headache and left upper abdominal pain for 2 days. After admission, her blood pressure was 158/112 mmHg accompanied with increased blood lipids and proteinuria. Ultrasonography did not show any abnormalities. The main diagnoses included twin pregnancy with abdominal pain of unknown aetiology, preeclampsia and hyperlipidaemia. Her blood pressure and symptoms did not improve after administration of medications. An emergency caesarean section and laparotomy were then performed. Intraoperatively, bright red non-coagulated blood was observed within the pelvis and removed. After two healthy female babies were delivered, pelvic exploration revealed haematomas in the broad ligaments bilaterally and haemostatic sutures and clips were applied to successfully treat the ruptured vein. In cases of unexplained abdominal pain accompanied with fetal distress and haemodynamic instability, especially in twin pregnancy that can cause uterus over-expansion and broad ligament over-stretch, the possibility of spontaneous uterine vein rupture should be considered. Rapid diagnosis, immediate fluid replacement and prompt surgical intervention are essential for the safety of the mother and child.
SLATE II is be a pragmatic, individually randomized evaluation to determine the effectiveness of the revised algorithm in increasing ART initiation, compared to standard care, among non-pregnant adult patients. Six hundred HIV-infected adult patients not yet on ART will be enrolled during a routine clinic visit and randomized to receive the intervention or standard care. Patients in the intervention arm will be administered a revised version of the SLATE screens, including the TB add-on; those found eligible under the algorithm will be offered immediate treatment initiation, while those who are not eligible will be referred for standard clinic care. Patients in the standard arm will be referred for ART initiation under standard clinic procedures. All care after the initial visit will be by the clinic under standard care. Primary outcomes will be ART initiation within 7 days of study enrollment and viral suppression within 8 months of study enrollment.

The study is being conducted at three healthcare facilities (clinics) in South Africa. In September 2017, the South African National Department of Health instructed all clinics to offer same-day ART initiation to eligible patients but provided little guidance on determining eligibility. SLATE II will help to create such guidance. If successful, it will improve on the SLATE approach to collecting and interpreting a minimum set of patient data that will avoid delaying treatment initiation for the majority of patients who are eligible for immediate ART, while deferring initiation in the minority who should not start immediately.
In the gum-chewing group, routine follow-up and additional gum-chewing training will be given (at least 10 minutes 4 times a day, preferably before meals and with sugar-free gum). Patients in the Gum Chewing Group will chew gum as recommended for 15 days. At the end of 15 days, all patients will come to the second interview. The same data collection methods will be repeated after 15 days. In the study, the chewing gum group will chew Vivident Xylit Full Fresh Mint Flavored Liquid Filled Sugar-Free Sweetener Gum. The contents of the gum; Sweeteners (Xylitol, Sorbitols, Mannitol, Maltitols, Aspartame, Acesulfame-K), Gum Yeast, Stabilizer (Glycerol), Flavorings, Natural Mint Flavoring, Maltodextrin, Starch, Emulsifiers (E473, Soy Lecithin), Green Tea Extract, Consistency Enhancers (Cellulose Gum, Xanthan Gum), Coconut Oil, Antioxidant (E321), Brightener (Carnauba Wax), Colorant (E133). There is no allergen warning.
BACKGROUND: Therapy-resistant constipation often is a frustrating clinical entity recognised by the persistence of infrequent and painful bowel movements faecal incontinence and abdominal pain despite intensive treatment. It is important to clearly define therapy-resistant constipation before children are subjected to invasive diagnostic and therapeutic procedures.
AIM: To conduct a systematic review determining how paediatric interventional studies define therapy-resistant constipation.
METHOD: We searched CENTRAL, MEDLINE, Embase, WHO ICTR and ClinicalTrials.gov. Studies that included patients with therapy-resistant constipation were identified. Data were extracted on criteria used for defining therapy-resistant constipation and reported using a meta-narrative approach highlighting areas of convergence and divergence in the findings.
RESULTS: A total of 1553 abstracts were screened in duplicate, and 47 studies were included in the review. There were at least seven definitions used in the paediatric literature to define medically resistant constipation. The term intractable was used in 24 articles and 21 used the term refractory to describe therapy-resistant constipation. Out of them, only 14 articles have attempted to provide an explicit definition including a predefined time and prior therapy. There were 10 studies without a clear definition for therapy-resistant constipation. The duration before being diagnosed as therapy-resistant constipation varied from 1 months to 2 years among studies. Seven studies employed the Rome criteria (Rome III or Rome IV) to characterising constipation while five adopted the Rome III and European and North American paediatric societies definition of paediatric gastroenterology, hepatology and nutrition guideline of management of constipation in children.
CONCLUSION: The current literature has no explicit definition for therapy-resistant constipation in children. There is a need for a detailed consensus definition to ensure consistency of future research and to avoid unnecessary and maybe even harmful, invasive diagnostic and therapeutic interventions.
PURPOSE: Despite having the highest medical needs by population for weight loss treatment, Pacific patients in Aotearoa New Zealand face substantial levels of attrition in publicly funded weight loss surgery programs. In collaboration with the Auckland City Hospital bariatric surgery team, a Pacific-led preoperative weight loss surgery program was co-designed, delivered, and evaluated between 2020 and 2023.
MATERIALS AND METHODS: This was a single-arm, prospective co-designed evaluation study that took place at Auckland City Hospital in Aotearoa New Zealand. Participants were Pacific patients (n = 14) referred to the weight loss surgery program. Survey and video diaries were analyzed to determine if the program had the potential to increase Pacific patient retention through the preoperative stage of weight loss surgery, increase surgery completion rates, and improve the quality of treatment experiences.
RESULTS: Nine out of 14 participants attended all preoperative sessions. Six participants subsequently underwent weight loss surgery. Program components that had positive impacts on patient success and satisfaction were accessibility, information quality, having Pacific role models, cultural safety, and the group support system. The patients found the program to be culturally anchored and there was support for the implementation of the program going forward.
CONCLUSION: This study demonstrated how a culturally anchored intervention can increase patient retention for those patients who may not respond to mainstream treatment. Adjusting existing preoperative weight loss surgery programs to integrate Pacific-led models of healthcare has the potential to increase Pacific patient resiliency to follow through with surgery.
BACKGROUND AND PURPOSE: We evaluated the hypothesis that central orexin application could counteract motion sickness responses through regulating neural activity in target brain areas.
EXPERIMENTAL APPROACH: Thec effects of intracerebroventricular (i.c.v.) injection of orexin-A and SB-334867 (OX1 antagonist) on motion sickness-induced anorexia, nausea-like behaviour (conditioned gaping), hypoactivity and hypothermia were investigated in rats subjected to Ferris wheel-like rotation. Orexin-A responsive brain areas were identified using Fos immunolabelling and were verified via motion sickness responses after intranucleus injection of orexin-A, SB-334867 and TCS-OX2-29 (OX2 antagonist). The efficacy of intranasal application of orexin-A versus scopolamine on motion sickness symptoms in cats was also investigated.
KEY RESULTS: Orexin-A (i.c.v.) dose-dependently attenuated motion sickness-related behavioural responses and hypothermia. Fos expression was inhibited in the ventral part of the dorsomedial hypothalamus (DMV) and the paraventricular nucleus (PVN), but was enhanced in the ventral part of the premammillary nucleus ventral part (PMV) by orexin-A (20 μg) in rotated animals. Motion sickness responses were differentially inhibited by orexin-A injection into the DMV (anorexia and hypoactivity), the PVN (conditioned gaping) and the PMV (hypothermia). SB-334867 and TCS-OX2-29 (i.c.v. and intranucleus injection) inhibited behavioural and thermal effects of orexin-A. Orexin-A (60 μg·kg-1) and scopolamine inhibited rotation-induced emesis and non-retching/vomiting symptoms, while orexin-A also attenuated anorexia with mild salivation in motion sickness cats.
CONCLUSION AND IMPLICATIONS: Orexin-A might relieve motion sickness through acting on OX1 and OX2 receptors in various hypothalamus nuclei. Intranasal orexin-A could be a potential strategy against motion sickness.
Patients in the cisatracurium/neostigmine group will receive 0.2 mg/kg of cisatracurium for neuromuscular paralysis during induction. Additional cisatracurium will be given to keep the patient at a neuromuscular depth of 1 twitch throughout the surgery until the last 30 minutes, during which the patient will be kept at 2 twitches.
A method of immunizing a mammalian patient against infection by a bacterial pathogen involves administering a pertussis or  Pseudomonas  antigen to the mammalian patient. The pertussis antigen is least one of a chaperonin protein GroEL from  Bordetella pertussis , or a fragment thereof; and an OmpA protein of  Bordetella pertussis , or a fragment thereof. The  Pseudomonas  antigen is least one of a chaperonin protein GroEL from  Pseudomonas aeruginosa , or a fragment thereof; and an OprF protein from  Pseudomonas aeruginosa , or an OmpA-domain fragment thereof. The bacterial pathogen expresses a protein having at least 45% identity to the pertussis antigen. The bacterial pathogen may be a gram-negative bacteria. The bacterial pathogen may be a bacteria from a genus  Escherichia , a genus  Enterococcus , a genus  Staphylococcus , a genus  Klebsiella , a genus  Acinetobacter , and a genus  Enterobacter.
Transcranial Direct Current Stimulation : 10 sessions twice a day during 5 days, with a sham stimulation during 20 minutes. Initial stimulation followed by turning off the device as to ensure blinding.
A  Candida albicans  bloodstream infections cause significant morbidity and mortality in hospitalized patients. Filament formation and adherence to host cells are critical virulence factors of  C. albicans . Multiple filamentation regulatory pathways have been discovered, however the downstream effectors of these regulatory pathways remain unknown. The cell surface protein, Als1p, is a downstream effector of the filamentation regulatory pathway and is regulated by Efg1p. Als1p mediates adherence to endothelial cells in vitro and is required for virulence. The blocking of adherence by the organism is described resulting from the use of a composition and method disclosed herein. Specifically, a pharmaceutical composition comprised of a gene product from the ALS1 gene family is administered as a vaccine to generate an immune response capable of blocking adherence of the organism.
In supine position, the ultrasound probe will be placed on in inguinal region, 1-2 cm below to the inguinal crease to identiy the subpectineal area. Patients in this group will receive subpectineal obturator nerve block under ultrasound guidance.
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to oncology, gynaecology. Skin incision is performed in 8th intercostal space. Pocket for the reservoir and canal 8–10 cm long for the catheter are formed in the subcutaneous cellular in blunt manner. Intraperitoneal catheter is inserted along the formed canal, which is attached to the reservoir by means of a fixing ring. Reservoir is fixed with three interrupted sutures; the catheter is filled with physiological saline with heparin and placed in a small pelvis. Laparotomy wound is closed, the HIPEC procedure is performed with the further performance of normothermal chemo-perfusion through the port system.EFFECT: method enables improving the treatment results, more effective exposure of the disseminated tumour process in the abdominal cavity, excluding the reservoir displacement in the subcutaneous fat during the patient's movements, effective removal of the ascitic fluid without the risk of complications.1 cl, 1 dwg, 1 ex
25 patients were included in the trial. Intervention period was 4 weeks with 2 months wash out phase. The screening visit of all volunteers before study start included volunteer information, signature of informed consent, anamnesis, medical history, ECG and blood routine analysis.

Efficacy parameters were measured at visit 1, 2, 3, and 4. Endothelial function and postprandial endothelial Reaction was tested using EndoPAT (validated diagnosis tool). Blood pressure was measured by volunteers over a period of 7 days before each visit. As additional parameters homocysteine and ADMA (assymmetric dimethyl arginine) were determed. For safety evaluation AEs (Adverse Events), CC (compliance control), tolerability, blood routine parameters and vital signs were assessed.
In patients with skeletal class III malocclusion (ANB angle \< 0,0) due to maxillary deficiency, rapid maxillary expansion appliances prepared on dental plaster models made of acrylic material covering all the upper dental posterior tooth surfaces were applied before the upper jaw was orthopedically brought forward with a face mask. This process was stopped when the expansion was made so that the palatal tubercles of the maxillary permanent first molars align with the buccal tubercles of the mandibular permanent first molars. Immediately afterwards, the petit-type face mask was applied to the hooks of the maxillary expansion device with the help of elastic bands and used continuously for at least 18 hours a day. After obtaining a positive overjet, the face mask appliance was used at night to ensure retention, and then the treatment was terminated.
Superpotent topical corticosteroids such as clobetasol propionate are highly effective in treating plaque psoriasis but are not indicated for long term use due to their side effects. Therefore, steroid-sparing combination and sequential regimens, in which the corticosteroid gets supplemented with a non-steroid medication, such as calcipotriol or tazarotene, have become the standard of care, especially in the management of localized psoriasis lesions. A new steroid-free 15% liquor carbonis distillate (LCD) solution (Psorent) was recently found to be more successful than 0.005% calcipotriol cream (Dovonex) at improving and delaying worsening of psoriasis symptoms in a controlled clinical trial. The goal of this pilot study is to evaluate if this LCD solution can be used in combination with acute topical corticosteroid therapy as a new steroid-sparing / enhancing regimen. We hope to explore the compatibility, patient tolerability, and clinical benefit of using LCD solution during and after treatment with clobetasol propionate in adults with moderate to severe plaque psoriasis. This is a randomized, double-blind, vehicle-controlled, bilateral study. Men and women 18 years of age or older, with chronic plaque psoriasis affecting less than or equal to 10% body surface area (BSA) in areas other than the scalp, face, palms, soles, axillae, and groin, are recruited. Those with a Physician Global Assessment (PGA) score greater than 3 and are in general good health will qualify as candidates. On one side of the body, LCD solution and clobetasol propionate will be administered twice daily for the first 2 weeks of treatment, followed by 4 weeks of LCD solution only, followed by 6 weeks of no treatment. On the second half of the body, subject will apply a vehicle solution and clobetasol propionate twice daily for the first 2 weeks, only the vehicle solution twice daily for the next four weeks, and then no treatment for the next 6 weeks. Subjects will be evaluated at weeks 2, 4, 6, 8, 10 and 12. investigators will use the PGA scale \[Clear (0) - Severe (5)\] to determine treatment effects as well as Target Lesion assessments of Erythema, Scaling, Induration and overall severity \[None (0) - Very Severe (4)\]. patients will also be required to complete Self-Assessment questionnaires on their psoriasis \[None (0) - Severe (6)\]. as well as an assessment of the study solution \[Excellent (9) - Poor (1)\]. . Photographs will be taken at each study visit and adverse events will be monitored throughout the study.
BACKGROUND: Recovering pathogenic bacteria and yeast from pediatric blood cultures and reliably distinguishing between pathogens and contaminants are likely to be improved by increasing the volume of blood submitted to microbiology laboratories for culturing beyond the low volumes that have historically have been used. The primary aim of this study was to assess whether the pathogen recovery rate would increase after implementation of a weight-based algorithm for determining the intended volume of blood submitted for culturing. Secondary aims were to: 1) evaluate the effects of the algorithm implementation on the blood culture contamination rate; 2) determine whether pathogens might be found more often than contaminants in several as opposed to single bottles when more than one bottle is submitted; and 3) describe the microbiological findings for pathogens and contaminants in blood cultures by applying a clinical validation of true blood culture positivity.
METHODS: A pre-post comparison of positivity and contamination rates after increasing the theoretical blood volume and number of blood culture bottles was performed, on the basis of a clinical validation of blood culture findings as pathogens vs contaminants.
RESULTS: We examined 5327 blood cultures, including 186 with growth (123 true positives and 63 contaminated). The rate of true positive blood cultures significantly increased from 1.6% (42/2553) pre to 2.9% (81/2774, p = .002) post intervention. The rate of contaminated blood cultures did not change significantly during the study period (1.4% [35/2553] pre vs 1.0% [28/2774], p = .222) post intervention), but the proportion of contaminated cultures among all positive cultures decreased from 45% (35/77) pre to 26% (28/109, p = .005) post intervention. A microorganism that grew in a single bottle was considered a contaminant in 35% (8/23) of cases, whereas a microorganism that grew in at least two bottles was considered a contaminant in 2% (1/49, p < .001) of cases. According to common classification criteria relying primarily on the identity of the microorganism, 14% (17/123) of the recovered pathogens would otherwise have been classified as contaminants.
CONCLUSION: Implementation of a weight-based algorithm to determine the volume and number of blood cultures in pediatric patients is associated with an increase in the pathogen recovery rate.
KDDP is a prospective, 12-month pilot study comparing the effects of the KDDP vs. CDC NDPP in patients with obesity and dysglycemia. KDDP is the Ketogenic Diet and Diabetes Demonstration Project arm. Individuals enrolled in the KDDP arm will attend a mandatory Weight Management class through the Center for Diabetes and Nutrition Education, and they will participate in a standard comprehensive lifestyle intervention program that is identical to that of the NDPP with the exception of dietary recommendations. Individuals in the KDDP arm will be educated on and follow a ketogenic diet (\<20g carbohydrates/day). They will receive guidance on tracking carbohydrate intake daily, and home point-of-care ketone breath testing will be performed at regular intervals to ensure that ketosis is being achieved and maintained. They will attend weekly educational sessions facilitated by trained dieticians. Individuals enrolled in the CDC NDPP arm will adhere to a low fat diet and receive identical follow up with the dieticians relative to those enrolled in the KDDP arm. Individuals in both arms will be matched for age, sex, weight, and A1c.

Baseline measures at study entry will include weight, height, systolic and diastolic blood pressure, heart rate, hemoglobin A1c, fasting plasma glucose, total cholesterol, triglycerides, HDL cholesterol, and LDL cholesterol. These parameters will be measured every 3 months throughout the study and at study completion. Additionally, participants in both groups will be consented to undergo CAC scanning at baseline and at 12 months to assess for any differences in dietary interventions on CAC scores.
b  : b  - Methyl - ethyl - glutaramic acid is prepared by treating b : b -methyl-ethyl-glutaric anhydride in water with ammonia followed by acidification with hydrochloric acid.  b  : b -Methyl-ethyl-dithioglutarimide is prepared by boiling methyl-ethyl-glutarimide in xylene with phosphorus pentasulphide. b : b  - Methyl - isobutyl-glutarimide is prepared by heating b  : b -methyl-isobutyl-glutaric acid with urea.  a  : b -Dimethyl - b  - ethyl - glutarimide is prepared by treating a  : a 1 - dicyano - b  : b  - methyl - ethyl-glutarimide with dimethyl sulphate in presence of sodium and absolute alcohol to give N - methyl - a  : a 1 - dicyano - a  - methyl - b  : b  - methyl-ethyl-glutarimide, converting this by treatment with sulphuric acid to N-methyl-a  : b  - dimethyl - b  - ethyl - dicarbamoyl - glutarimide, hydrolysing this with sulphuric acid to a  : b  - dimethyl - b  - ethyl - glutaric acid, distilling this to give a  : b -dimethyl-b -ethyl-glutaric acid anhydride and heating this with urea.ALSO:A pharmaceutical preparation comprising a medicinal barbiturate and a substituted glutaric acid derivative selected from b ,b -methyl ethyl glutaramic acid, b ,b -methyl ethyl dithioglutarimide, b -spirocyclopentane glutarimide, b -spirocyclohexane glutarimide, b -spirocycloheptane glutarimide, b ,b - dimethyl glutarimide, b ,b  - diethyl glutarimide, b ,b  - methyl isobutyl glutarimide, b ,b -methyl-n-propyl glutarimide, a ,b ,b  - trimethyl glutarimide, a ,b  - dimethyl - b  - ethyl glutarimide, a - ethyl - b ,b  - dimethyl glutarimide and camphoric acid imide, or mixtures thereof in an amount insufficient to interfere with a therapeutic dose of barbiturate but sufficient to overcome the toxic effects of overdose.  Specified barbiturates are phenobarbitone, amylobarbitone, butobarbitone, pentobarbitone sodium, quinolbarbitone sodium, hexobarbitone sodium.  The proportion of substituted glutaric acid derivative should be 5-200 per cent, preferably 25-150 per cent, by weight of the barbiturate.  In addition the preparation may include b ,b -methyl ethyl glutarimide; mild stimulants such as caffeine and amphetamine; mild sedatives such as sodium bromide; hypnotics such as chloral and paraldehyde; analgesics such as aspirin, phenacetin and codeine; antiasthmatics such as ephidrine; anticholinergics such as atropine; anticonvulsants such as hydantoin. The preparation may be in the form of an injection, suppository, tablet, elixir or capsule and may embody an agent when in capsule or tablet form, delaying the release of the substituted glutaric acid derivative.  In tablet form the barbiturate may form a layer compressed over a core containing substituted glutaric acid derivative.